Analyzing Pacira BioSciences (NASDAQ:PCRX) and Gyre Therapeutics (NASDAQ:GYRE)

Pacira BioSciences (NASDAQ:PCRX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Volatility & Risk

Pacira BioSciences has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider and Institutional Ownership

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Pacira BioSciences and Gyre Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41 million	1.37	$7.03 million	$0.35	71.46
Gyre Therapeutics	$116.59 million	6.69	$5.03 million	($0.21)	-33.33

Pacira BioSciences has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pacira BioSciences and Gyre Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1	4	4	0	2.33
Gyre Therapeutics	2	0	1	0	1.67

Pacira BioSciences currently has a consensus price target of $30.14, indicating a potential upside of 20.52%. Gyre Therapeutics has a consensus price target of $16.00, indicating a potential upside of 128.57%. Given Gyre Therapeutics’ higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Gyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Summary

Pacira BioSciences beats Gyre Therapeutics on 10 of the 14 factors compared between the two stocks.

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.